• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Takeda

Finance

Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease (IBD)

April 5, 2018 Microbiome Times

Osaka, Japan and Somerville, MA, April 5 2017 – Finch Therapeutics, a privately held microbiome engineering company, and Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), today announced a global collaboration agreement to jointly develop FIN-524. […]

QIAGEN’S NEW HIGH-THROUGHPUT BENCHTOP AUTOMATION SYSTEM

Sign Up to Free Newsletter

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
  • Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
    November 17, 2025
sign up

Sign up to the Microbiome Times newsletter